Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pilot Study of Raltegravir Lipodystrophy IISP

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Southern California Institute for Research and Education.
Recruitment status was  Recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Southern California Institute for Research and Education Identifier:
First received: July 14, 2010
Last updated: May 16, 2012
Last verified: May 2012

The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with the chronic use of NRTIs. Changing the HAART regimen in patients with a sustained virological response from a PI plus NRTI to a regimen of the PI plus raltegravir will likely result in continued virologic efficacy.

Condition Intervention
HIV Infection
Drug: Raltegravir

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment

Resource links provided by NLM:

Further study details as provided by Southern California Institute for Research and Education:

Primary Outcome Measures:
  • Determine if the substitution of raltegravir for 2 NRTI's in patients with evidence of peripheral lipoatrophy and who have sustained HIV virological suppression will result in evidence of an increased in volume of peripheral fat within one year. [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determining whether the patients will continue to have sustained virological suppression upon switching to a raltegravir-based regimen. [ Time Frame: eighteen months ] [ Designated as safety issue: No ]
  • Determining what, if any, adverse effects the patients may develop.. [ Time Frame: eighteen months ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: October 2010
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Raltegravir
    60 tablets (30-day supply)
Detailed Description:

A prospective, non-controlled, non-randomized, single center study of a treatment regimen of a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in combination with raltegravir in patients with HIV-1 infection who have been, and continue to be, fully controlled on a standard HAART regimen of a PI or an NNRTI plus 2 NRTIs, and the effect of the change in regimen on peripheral fat distribution.

This pilot study will contain 30 patients who will be followed over a period of one year starting from the date of the medication change from an NRTI-based regimen to a raltegravir-based NRTI-sparing regimen. Potential changes in fat distribution (fat content as assessed by fat volume) will be measured with serial MRI's of the thighs.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV-1 positive
  2. Any patient on a boosted PI plus 2 NRTIs.
  3. Visual evidence peripheral fat wasting
  4. HIV-1 viral load fully suppressed at least 9mths.

Exclusion Criteria:

  1. Historical resistance to PI patient receiving
  2. No prior exposure to raltegravir, elvitegravir, other HIV-1 integrase inhibitor.
  3. No contraindications to serial MRI scanning.
  4. No contraindications to utilization of raltegravir.
  5. Not currently receiving any medications drug-drug interaction w/ raltegravir.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01164605

Contact: Stephen M Berman, M.D.,Ph.D. (562) 826-8000 ext 2841
Contact: Judy A Gerken, NP (562) 826-8000 ext 5452

United States, California
VA Long Beach Healthcare System Recruiting
Long Beach, California, United States, 90822
Sponsors and Collaborators
Southern California Institute for Research and Education
Merck Sharp & Dohme Corp.
Principal Investigator: Stephen M Berman, M.D., Ph.D. Southern California Institute for Research and Education
  More Information

Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. D. Ripamonti, F. Maggiolo, E. Bombana, et al. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2010, Cape Town, South Africa.
Raltegravir without a protease inhibitor is highly efficacious in heavily pre-treated individuals. D. Skiest, C. Cohen, D. Barker, M. Gottlieb, et al. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2010, Cape Town, South Africa.

Responsible Party: Southern California Institute for Research and Education Identifier: NCT01164605     History of Changes
Other Study ID Numbers: #37977
Study First Received: July 14, 2010
Last Updated: May 16, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Southern California Institute for Research and Education:
HIV-1 integrase inhibitor
Fat Waste

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases processed this record on February 25, 2015